Comparison of the Efficacy and Safety of SGLT2i and GLP-1 Receptor Agonists in Obese Patients With Kidney Disease

NCT06344247 · Unknown status

Last updated 2026-05-28

This clinical trial compares two diabetes medications, SGLT2 inhibitors and GLP-1 receptor agonists, in overweight or obese adults with kidney disease to see how they affect protein levels in urine.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Not applicable Not a phased drug trial (e.g. a device or behavioral study).

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 48 people Planned (estimated).

Who can join Ages 18–75 · all sexes

Timeline Started 2023-09 · est. completion 2025-12

Where 1 site · China

What this study is testing ClinicalTrials.gov NCT06344247 ↗

Description as written by the study sponsor.

The goal of this clinical trial is to exploring the changes in 24-hour urinary protein and renal function in obese patients with kidney disease after the application of sodium glucose cotransporter 2 inhibitors (SGLT2i) and glucagon like peptide-1 receptor agonists (GLP-1RA). Eligible patients were randomly and non-blindly allocated to four groups in a 1:1:1:1 ratio.The first group is the optimized treatment group, and patients in this group maintain the maximum dose/maximum tolerated dose of RAS blocker therapy. The second group is the optimized treatment + SGLT2i group. Participants in this group are titrated to the target dose (10 mg qd) in combination with dapagliflozin on the basis of optimized treatment. The third group is the optimized treatment + GLP-1RA group. Participants in this group will be titrated to the target dose (1mg qw) in combination with semaglutide on the basis of optimized treatment. The last group is the optimized treatment + SGLT2i + GLP-1RA treatment group, that is, based on the optimized treatment, combined with dapagliflozin titrated to the target dose (10 mg qd) and semaglutide titrated to the target dose (1 mg qw).

Treatments tested

RAS inhibitors：Losartan®️/Valsartan®️ Drug

Losartan®️/Valsartan®️ : maintain the maximum dose/maximum tolerated dose.
dapagliflozin：Forxiga®️ Drug

Forxiga®️ : titrated to the target dose (10 mg qd).
simagliptin：Forxiga®️ also known as Semaglutide®️ Drug

Semaglutide®️ : titrated to the target dose (1 mg qw).

Main thing measured	Change of 24-hour urine protein quantification
Sponsor	RenJi Hospital
Conditions studied	Obesity, Chronic Kidney Diseases
GLP-1 drugs	—

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06344247 ↗